Recent advances in atypical antipsychotics

IDrugs

Volumn 3, Issue 8, 2000, Pages 920-934

  Armer, Richard ^a   Miller, David J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005443604     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Jackson DM, Dursan S, Denovan-Wright EM: Recent advances in potential atypical antipsychotics: Past, present and future hopes - preclinical and clinical considerations. IDrugs (1999) 2(9):886-895.
2. Wong AHC, Sanyal S, Knapp MGL, Van Tol HHM: Potential therapeutic targets for schizophrenia. Emerging Ther Targets (1999) 3(4):571-586.
3. Nakazato A, Okuyama S: Recent advances in novel atypical antipsychotic agents: potential therapeutic agents for the treatment of schizophrenia. Exp Opin Ther Pat (2000) 10(1):75-98.
4. Bates B: Use atypicals first for schizophrenia. Clin Psychiatry News (1999) 27(8):1-6.
5. McEvoy JP, Scheifer PL, Frances A: The Expert Consensus Guideline Series: Treatment of Schizophrenia 1999. J Clin Psychiatry (1999) 60(Supp. 11):3-80.
6. Canales PL, Olsen J, Miller AL, Crismon ML: Role of atypical antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs (1999) 12(3):179-188.
7. Sherman C: Olanzapine or clozapine for resistant schizophrenia. Clin Psychiatry News (1999) 27(8):12.
8. Kilian JG, Kerr K, Lawrence C, Celermajer DS: Myocarditis and cardiomyopathy associated with clozapine. Lancet (1999) 354:1841-1845.
9. Current problems in pharmacovigilance. Joint Publication of the Committee on Safety of Medicines and the Medicines Control Agency (1998) 24:8.
10. Digital Gene Technologies: Digital Gene Technologies and the Mental Health Research Institute of Victoria, Australia, to study clozapine-induced agranulocytosis in the treatment of schizophrenia. Press Release. (1999) 14 June
11. Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan H, Chasnov MA: Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest (1999) 18(2):99-104.
12. Tariot P et al.: Clinical improvement and tolerability is maintained long term in elderly patients with psychotic disorders treated with Seroquel® (quetiapine). American Psychiatric Association Annual Meeting (1999) Washington DC.
13. McManus DQ, Arvantis LA, Kowalcyk BB: Seroquel® (quetiapine fumerate), a novel antipsychotic: Experience in elderly patients with psychotic disorders. J Clin Psychiatry (1999) 60(5):292-298.
14. Schneider L, Yeung P, Sweitzer D, Arvanitis L: Effects of Seroquel® (quetiapine) on reducing hostility and psychosis in patients with Alzheimer's disease. American Psychiatric Association Annual Meeting (1999). Washington DC.
15. Juncos J, Yeung P, Sweitzer D, et al: Seroquel® (quetiapine) improves psychotic symptoms associated with Parkinson's disease. American Psychiatric Association Annual Meeting (1999) Washington DC.
16. Friedman J, Fernandez H, Jacques C, Rosenfield M: Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. American Psychiatric Association Annual Meeting (1999) Washington DC.
17. Emsley R, Raniwalla J, Bailey P, Jones A: Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenia patients partially responsive to conventional antipsychotic treatment. American Psychiatric Association Annual Meeting (1999) Washington DC.
18. Velligan D, Newcomer J, Pultz, Csamansky J et al.: Changes in cognitive function with quetiapine (Seroquel) versus haloperidol. American Psychiatric Association Annual Meeting (1999) Washington DC.
19. Reinstein M: Management of weight gain and diabetes by clozapine-seroquel combination therapy: Preliminary findings. American Psychiatric Association Annual Meeting (1999) Washington DC.
20. Sajatovic M, Brescan D, Perez D, DiGiovannia S, Hattab H: Seroquel® in the treatment of neuroleptic dependent serious mood disorders. American Psychiatric Association Annual Meeting (1999) Washington DC.
21. Tahami H, Goodnick P, Doran W, Hernandez M, Freund B: Quetiapine in psychotic depression. American Psychiatric Association Annual Meeting (1999) Washington DC.
22. Bondolfi G, Dufour H, Patris JP, May U, Billeter C, Eap B, Baumann P: Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study. Am J Psychiatry (1998) 155:499-504.
23. Conley RR, Mahmoud R: Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. US Psychiatric and Mental Health Congress Atlanta, (1999) USA.
24. Lecomte P, De Hert M, van Dijk M, Nuijten M, Nuyts G, Persson U: A 1-year cost-effectiveness model for the treatment of chronic schizophrenia with acute exacerbations in Belgium. Value in Health (2000) 3:1.
25. Danysz W: CX-516. Curr Opin Cent Peripheral Nerv Syst Invest Drugs (1999) 1(3):388-396.
26. Johnson SA, Luu NT, Herbst TA, Knapp R, Lutz D, Arai A, Rogers GA, Lynch G: Synergistic interactions between AMPAkines and antipsychotic drugs. J Pharm Exp Ther (1999) 289:392-397.
27. Bennett MR: Monaminergic synapses and schizophrenia: 45 years of neuroleptics. J Pschycopharmacol (1999) 12(3):289-304.
28. Strange PG: Mechanism of action of antipsychotic drugs. Biochem Soc Trans (1999) 27:175-178.
29. Greengard P, Allen PB, Nairn AC: Beyond the dopamine receptor: the DARPP32/protein phosphatase-1 cascade. Neuron (1999) 23:435-447.
30. Gerlach J, Lublin H, Peacock L: Dopamine D, receptor antagonists in rodents, in primates and in humans. In: Alfred Benzon Symposium 38: Schizophrenia, an integrated view. Fog R, Gerlach J, Hemmingsen R (Eds) Munksgaard, Denmark (1995) 300-309.
31. 2 receptor antagonist, on Fos protein expression in the rat forebrain. Pharmacol Biochem Behav (1999) 63(4):535-541
32. Murasaki M: Clinical effects of perospirone on schizophrenia: a double-blind study with haloperidol. 21st Collegium Internationale Neuro-psychopharmacologicum Congress (1998) Glasgow.
33. Sasa M, Amano T: Unique pharmacological profile of a novel antipsychotic drug, aripiprazole (OPC-14597). CNS Drug Rev (1997) 3(1):24-33.
34. 1A-adrenergic affinity and a low potential for extrapyramidal side effects. J Med Chem (1994) 37(8):1060-1062.
35. Wu WN, McKown LA, Takacs AR, Jones WJ, Reitz AB: Biotransformation of the antipsychotic agent, mazapertine, in dog - mass spectral characterisation and identification of metabolites. Xenobiotica (1999) 29(5):453-466.
36. RWJ-37796. Annu Drug Data Reports (1993) 15(11):999.
37. Wright JL, Caprathe BW, Downing DM, Glase SA, Heffner TG, Jaen JC, Johnson SJ, Kesten SR, MacKenzie RG, Meltzer LT, Pugsley TA, Smith SJ, Wise LD, Wustrow DJ: The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents. J Med Chem (1994) 37(21):3523-3533.
38. Wright JL, Downing DM, Feng MR, Hayes RN, Heffner TG, MacKenzie RG, Meltzer LT, Pugsley TA, Wise LD: Identification, characterisation and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1-yl)methyl]pyridine (Cl-1007), a dopamine autoreceptor agonist and potential antipsychotic agent. J Med Chem (1995) 38(26):5007-5014.
39. Shiloh R, Nutt D, Weizman A: Atlas of psychiatric Pharmacotherapy. (1999) Martin Dunitz Ltd, UK.
40. 3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann NY Acad Sci (1999) 877:595-613.
41. 3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J Neural Transm (1998) 105(6-7):719-734.
42. 4 receptors: Basic and clinical status. Int J Neuropschopharmacol (1999) 2:41-58.
43. Pharmacia and Upjohn: Annu Drug Data Report (1996) 18(5):409.
44. TenBrink RE, Bergh CL, Duncan JN, Harris DW, Huff RM, Lahti RA, Lawson CF, Lutzke BS, Martin IJ, Rees SA, Schlachter SK, Sih JC, Smith WM: (S)-(-)-4-[4-[2-(Isochroman-2-yl)ethyl]-piperazin-1-yl]benzenesulfonamide, a selective dopamine D(4) antagonist. J Med Chem (1996) 39(13):2435-2437.
45. BASF Knoll: (+)-LU-111995. Annu Drug Data Reports (1997) 19(5):399.
46. 4 and 5-hydroxytripamine 2A antagonist: Pharmacological characterisation and first clinical experience, Eur Neuropsychopharmacol (1998) 8(Suppl 2):Abst P.2.122.
47. Sosunov EA, Gainullin RZ, Danilo Jr P, Anyukhovsky EP, Kirchengast M, Rosen MR: Electrophsyiological effects of LU111995 on canine hearts: In vivo and in vitro studies. J Pharm Exp Ther (1999) 290:146-152.
48. 2 template. J Med Chem (1999) 42(11):2007-2020.
49. 4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. J Pharmacol Exp Ther (1997) 283(3):1256-1263.
50. 4 dopamine receptor antagonist (L-745-870) in acutely psychotic inpatients with schizophrenia. Arch Gen Psychiatry (1997) 54:568-572.
51. 4 receptor. J Med Chem (1996) 39:1941-1942.
52. 2 Antagonists: a concept for the design of schizophrenia. Curr Pharm Design (1997) 3:367-390.
53. Guitart X, Ballarin M, Codony X, Dordal A, Farre AJ, Frigola J, Merce R: E-5842: antipsychotic sigma ligand. Drugs Future (1999) 24(4):386-392.
54. 6 receptor antagonist. J Med Chem (1999) 42(2):202-205.
55. Martinez MC: Famotidine in the management of schizophrenia. Ann Pharmacother (1999) 33:742-744.
56. Tamminga C: Glutamatergic aspects of schizophrenia. Br J Psychiatry (1999) 174(Suppl 37):12-15.
57. Robinson M, Coyle, JT: Glutamate and related acidic excitatory neurotransmitters: from basic science to clinical application. FASEB J (1987) 1:446-455.
58. Armer RE: Inhibitors of mammalian central nervous system selective amino acid transporters. Curr Med Chem (2000) 7(2):199-211.
59. Bridges RJ, Kavanaugh MP, Chamberlin AR: A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system. Curr Pharm Design (1999) 5:363-379.
60. Bergeron R, Meyer TM, Coyle JT, Greene RW: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA (1998) 95:15730-15734.
61. Pellicciari R, Costantino G: Metabotropic G-protein-coupled glutamate receptors as therapeutic targets. Curr Opin Chem Biol (1999) 3:433-440.
62. Moghaddam B: Glutamate and schizophrenia. Sci Med (1999):22-41.
63. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe, T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD: Design, synthesis and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem (1997) 40:528-537.
64. Moghaddam B, Adams BW: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science (1998) 281:1349-1352.
65. Monn JA, Valli MJ, Massey SM, Hansen MM, Kress TJ, Wepsiec JP, Harkness AR, Grutsch JL, Wright RA, Johnson BG, Andis SL, Kingston A, Tomlinson R, Lewis R, Griffey KR, Tizzano JP, Schoepp DD: Synthesis, pharmacological charcterization, and molecular modelling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors. J Med Chem (1999) 42:1027-1040.
66. Nakazato A, Ohta K, Sekiguti Y, Okuyama S, Chaki S, Kawashima Y, Hatayama K: Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine sigma ligands as potential antipsychotic drugs. J Med Chem (1999) 42:1076-1087.
67. Nakazato A, Kumagai T, Ohta K, Chaki S, Okuyama S, Tomisawa K: Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-dipropyl-4-methoxy-3-(2-phenylethoxy)phenylethylamine to discover sigma-1 ligands. J Med Chem (1999) 42:3965-3970.
68. Azzi M, Betancur C, Sillaber I, Spanagel R, Rostene W, Berod A: Repeated administration of the neurotensin antagonist SR 48692 differentially regulates mesocortical and mesolimbic dopaminergic systems. J Neurochem (1998) 71(3):1158.
69. Zachrisson O, de Belleroche J, Wendt KR, Hirsch S, Lindefors N: Cholecystokinin CCK-B receptor mRNA isoforms: expression in schizophrenic brains. NeuroReport (1999) 10:3265-3268.
70. Leonard S, Adler LE, Olincy A, Breese CR, Gault J, Ross RG, Lee M, Cawthra E, Nagamoto HT, Freedman R: The role of nicotine and nicotine receptors in psychopathology. In: Neuronal nicotinic receptors: pharmacology and therapeutic opportunities. Americ SP, Brioni JD (Eds), Wiley-Liss, USA (1999) 307-321.
71. 2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists. Ann Psychiatr (1999) 33:480-488.
72. Wassef AA, Dott SG, Harris A, Brown A, O'Boyle M, Meyer III WJ, Rose RM: Critical review of GABA-ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol (1999) 19(3):222-232.
73. Goodman AB: Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA (1998) 95:7240-7244.
74. SUMITOMO PHARMACEUTICALS CO LTD (Ishizumi K, Antoku F, Maruyama I, Kojima A): Imide derivatives, their production and use. EP-00196096 (1985).
75. OTSUKA PHARMACEUTICAL CO LTD (Oshiro Y, Sato S, Kurahashi N): Carbostyril derivatives. EP-00367141 (1990).
76. HOECHST ROUSSEL PHARMACEUTICALS INC (Strupczewski JT, Helsley GC, Chiang Y, Bordeau KJ, Nemoto PA, Glamkowski EJ): Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analgetics. EP-00730452 (1995).
77. DAINIPPON PHARMACEUTICALS CO LTD (Hino K, Kai N, Sakamoto M, Kon T, Oka M, Furakawa K, Ochi Y): 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical compositions containing the same. EP-00385237 (1989).
78. MCNEIL INC (Reitz AB): Novel 4-arylpiperazines and 4-arylpiperidines. WO-09304682 (1993).
79. WARNER-LAMBERT CO (Caprathe BW, Downing DM, Jaen JC, Johnson SJ, Smith III WJ, Wise LD, Wright J, Wustrow DJ): 1,3-Substituted cycloalkenes and cycloalkanes as central nervous system agents. US-05314896 (1994).
80. KNOLL AKTIENGESELLSCHAFT (Birch AM, Bradley PA): Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them. WO-09829415 (1998).
81. FERRIER INTERNACIONAL SA (Foguet R, Bolos J, Sacristan A, Ortiz JA): 4-p-Fluorobenzoyl-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis and schizophrenia. WO-09525733 (1995).
82. THE UPJOHN CO (Ten Brink RE, Ennis MD, Lin C-H, Lahti RA, Romero AG, Sih JC): Heterocyclic compounds for the treatment of CNS and cardiovascular disorders. WO-09518118 (1995).
83. BASF AG (Steiner G, Unger L, Behl B, Teschendorf H-J, Munschauer R): N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung. DE-04243287 (1992).
84. ALLEUX BIOPHARMACEUTICALS INC (Tehim A, Fu J-M, Rakhit S): N-Heterobicyclyl or -piperidinyl tricyclic derivatives useful as dopamine receptor ligands. WO-09517400 (1995).
85. AKZO NOBEL NV (Rae DR, Jaap DR): Substituted piperidine derivatives. WO-09919324 (1999).
86. NEUROGEN CORP (Chen X, Wasley JWF): Substituted thienocyclopyrazoles: dopamine receptor subtype specific ligands. WO-09964425 (1999).
87. NEUROGEN CORP (Chen X, Wasley JWF): Substituted 1-aryl-3-benzylaminopyrolidine: dopamine receptor subtype specific ligands. WO-09964396 (1999).
88. THE ROCKEFELLER UNIVERSITY (Nishi A, Snyder GL, Fienberg AA, Greengard P): Use of an inhibitor of the dephosphorylation of DARPP-32 for treating schizophrenia. WO-09920273 (1999).
89. AMERICAN HOME PRODUCTS CORP (Nelson JA, Kanzelberger MA, Mewshaw RE): 4-Amino-(ethylamino)-oxindole dopamine autoreceptor agonists. WO-09952870 (1999).
90. AMERICAN HOME PRODUCTS CORP (Mewshaw RE, Nelson JA, Shah US): 4-Aminoalkoxy-1,3-dihydrobenzoimidazol-2-one dopamine autoreceptor agonists. US-05990144 (1999).
91. AMERICAN HOME PRODUCTS CORP (Kelly MG, Kang YH): Antipsychotic derivatives. WO-09955672 (1999).
92. AMERICAN HOME PRODUCTS CORP (Nelson JA, Mewshaw RE, Shah US): 4-Aminoalkoxy-1,3-dihydro-benzoimidazol-2-thiones. US-05972958 (1999).
93. AMERICAN HOME PRODUCTS CORP (Mewshaw RE, Verwijs AJ): 4-Aminoethoxyindazoles derivatives. US-05872144 (1999).
94. AMERICAN HOME PRODUCTS CORP (Stack GP): Azaheterocyclymethyl derivatives of 2,3,8,9-tetrahydro-7H-1,4-dioxino (2,3-e) indol-8-one. US-05869490 (1999).
95. AMERICAN HOME PRODUCTS CORP (Nelson JA, Shah US, Mewshaw RE): 5-Aminoalkoxy-1, 4-dihydroquinoxaline-2, 3-diones. US-05922715 (1999).
96. AMERICAN HOME PRODUCTS CORP (Mewshaw RE, Webb MB): 4-Aminoethoxy indoles. US-05958965 (1999).
97. FERRER INTERNACIONAL SA (Foguet R, Bolos J, Sacristan A Castello JM, Ortiz JA): 7-[(Piperidin-1-yl)propoxy]-chromen-4-one derivatives, their preparation and their pharmaceutical use. WO-09935144 (1999).
98. 3 receptors. WO-09964412 (1999).
99. 3 receptors. WO-09959974 (1999).
100. 2 ligands. US-05936000 (1999).
101. PHARMACIA & UPJOHN CO (Romero AG, Leiby JA): Phenylsulfonamide-phenylethylamines useful as dopamine receptors. WO-09958499 (1999).
102. ADIR & CO (Peglion JL, Harmange JC, Millan M, Lejeune F): Disubstituted trans-3,4,4a,5,6,10b-hexahydro-2H-napht(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical compositions containing them. EP-00899267 (1999).
103. BASF AG (Blank S, Starck D, Treiber H-J, Koser S, Schaefer B, Thyes M, Hoeger T): 2-(3-(4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl)propylmercapto) pyrimidin-4-ol-fumarat. DE-19735410 (1999).
104. BASF AG (Starck D, Blank S, Treiber H-J, Unger L, Neumann-Schultz B, Le-Bris T-M, Teschendorf H-J, Wicke K): Triazolverbindungen und Deren Verwendung. DE-19728996 (1999).
105. 3 dopaminergic receptor. WO-09856778 (1998).
106. HOECHST MARION ROUSSEL INC (Wang X, Fu J-M, Tresurywala AM): Preparation of troponylpiperazines as dopamine D4 receptor ligands. US-05998414 (1999).
107. NIHON NOHYAKU CO LTD; TAISHO PHARMACEUTICAL CO LTD (Nagamine M, Gotoh M, Yoshida M, Nakazato A, Kumagai T, Chaki S, Tomisawa K): Arylpiperidine derivatives and use thereof. WO-09947515 (1999).
108. NIHON NOHYAKU CO LTD; TAISHO PHARMACEUTICAL CO LTD (Nakazato A, Kumagai T, Chaki S, Tomisawa K, Nagamine M, Gotoh M, Yoshida M): Heteroaromatic derivatives. WO-09947513 (1999).
109. 4 receptor antagonists. US-05945421 (1999).
110. WARNER-LAMBERT CO (Conner DT, Johnson SJ, Kesten SR, Miller SR, Unangst PC, Wise LD, Lawrence D): Compounds and method of treating psychosis and schizophrenia. US-05916914 (1999).
111. 4 receptor antagonist. US-05885994 (1999).
112. 4 receptor antagonists. US-05922719 (1999).
113. NEUROGEN CORP (He X-S): 2-Aminoalkylaminoquinolines; dopamine receptor subtype specific ligands. US-5972945 (1999).
114. 4 receptor antagonists. WO-09943670 (1999).
115. 4 ligands. WO-09856786 (1998).
116. 4-antagonistic activity. WO-09940067 (1999).
117. 4-agonistic activity. WO-09940068 (1999).
118. 4 receptor) activity. EP-00953567 (1999).
119. PFIZER PRODUCTS INC (Fliri AFJ, Majchrzak MJ, Seymour PA, Zorn SH, Rollema H): 2-(4-Aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives. WO-09909025 (1999).
120. 4 receptor ligands. WO-09900386 (1999).
121. MERRELL Dow PHARMACEUTICALS INC (Carr AA, Wiech NL): N-Aralkyl piperidinemethanol derivatives. EP-00208235 (1987).
122. RHÔNE-POULENC SANTÉ (Comte MT, Gueremy C, Malleron JL, Mignani S, Peyronel JF, Truchon A): (Aza)naphthalenesultam derivatives, process for their preparation and drugs containing same. EP-00350403 (1990).
123. SANOFI (Cogny C, Labeeuw B, Guele P, Rinaldi M): Propenone oxime ethers, method for their preparation and pharmaceutical compositions containing them. EP-00373998 (1990).
124. AMERICAN HOME PRODUCTS CORP (Kelly, MG, Kang YH): Antipsychotic indolyl derivatives. WO-09955672 (1999).
125. ELI LILLY & CO (Tollefson GD): Olanzapine (Zyprexa) in combination with fluoxetine (Prozac), lithium or anticonvulsant for therapy of refractory depression. EP-00958824 (1999).
126. 1 receptor ligands. WO-09952907 (1999).
127. ADIR ET CO (Peglion J-L, Goument B, Millan M, Newman-Tancredi A, Dekeyne A): Indanol derivatives, process for their preparation and pharmaceutical compositions containing them. EP-00906912 (1999).
128. H LUNDBECK A/S (Moltzen EK, Perregaard JK, Mikkelsen I, Smith GP): Indole and 2,3-dihydroindole derivatives, their preparation and use. WO-09905140 (1999).
129. ASTRA AB (Berg S, Linderberg M, Ross S, Thorberg S-O, Ulff B): Substituted 1,2,3,4-tetrahydronaphthalene derivatives. WO-09905134 (1999).
130. SYNTHÉLABO (Sevrin M, De Peretti D, Marabout B, Jocelyne R, Pascal G, Machnik D): Derives de 8-azabicyclo[3.2.1]octane-3-methanamine, leur preparation et leur application en therapeutique. FR-02769629 (1999).
131. 2A receptor antagonists. WO-09947511 (1999).
132. 2A receptor antagonists. WO-09911641 (1999).
133. 2A receptor ligands. WO-09911619 (1999).
134. WASHINGTON UNIVERSITY (Olney JW, Farber NB): Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction. US-05902815 (1999).
135. AKZO NOBEL NV (Leysen D, Kelder J): Novel aryl-hydro naphthalenal kanamines. WO-09958490 (1999).
136. 2 antagonists. US-05863923 (1999).
137. 4 Agonists and antagonists. EP-00908459 (1999).
138. DAINIPPON PHARMACEUTICAL CO LTD (Kato S, Toyotomi Y, Tateishi H, Harada H, Yoshida N, Morikage K, Morikage Y): 1-[(1-Substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds. WO-09955674 (1999).
139. 4 ligands. WO-09850381 (1998).
140. SMITHKLINE BEECHAM PLC (Bromidge SM, Moss SF): Novel compounds. WO-09937623 (1999).
141. F HOFFMAN LA ROCHE AG (Bös M, Hunkeler W, Riemer C): Benzosulfone derivatives. EP-00930302 (1999).
142. 6 receptor affinity. EP-00941994 (1999).
143. Slassi A, Edwards L, O'Brien A, Xin T, Tehim A: 3-(2-Pyrrolidinylmethyl)-indole compounds having 5-HT6 affinity. WO-9947516 (1999).
144. 7 receptor. JP-11189585 (1999).
145. SCHERING CORP (Vaccaro WD, Wolin RL, Solomon DM, Aslanian RG, Piwinski JJ, Rosenblum SB): Imidazoylalkyl substituted with a five, six or seven membered heterocyclic ring containing one nitrogen atom. WO-09924421 (1999).
146. TOKYO TANABE CO LTD (Okuma S, Katsura, M, Iino, T): Partial agonist of N-methyl-D-aspartic acid receptor. JP-11217332 (1998).
147. TROPHIX PHARMACEUTICALS INC (Ognyanov VI, Borden L, Bell SC, Zhang J): Pharmaceutical for treatment of neurological and neuropsychiatric disorders. WO-09745115 (1997).
148. TROPHIX PHARMACEUTICALS INC (Ognyanov VI, Borden L, Bell SC, Zhang J): Pharmaceutical for treating of neurological and neuropsychiatric disorders. WO-09745423 (1997).
149. ALLEUX NEUROSCIENCES INC (Ognyanov VI, Borden L, Bell SC, Zhang J): Pharmaceutical for treating of neurological and neuropsychiatric disorders. US-06001854 (1999).
150. JANSSEN PHARMACEUTICA NV (Luyten WHML, Janssens FE, Kennis LEJ): Glycine transport inhibitors. WO-09944596 (1999).
151. JANSSEN PHARMACEUTICA NV (Luyten WHML, Janssens FE, Kennis LEJ): Glycine transport inhibitors. WO-09945011 (1999).
152. AKZO NOBEL NV (Gibson SG, Jaap DR, Thorn SN, Gilfillan R): Aminomethyl carboxylic acid derivatives. WO-0007978 (2000).
153. COCENSYS INC (Upasani R, Cai SX, Lan NC, Wang Y, Field G, Fick DB): Substituted quinazolines and analogs and the use thereof. WO-09944612 (1999).
154. COCENSYS INC (Xia H, Cai SX, Lan NC, Wang Y, Field G): Substituted 2,3-benzodiazepin-4-ones and the use thereof. US-05891871 (1999).
155. NEUROSEARCH A/S (Gouliaev AH, Larsen M, Varming T, Mathiesen C, Johansen TH, Scheel-Kruger J, Olsen GM, Nielsen EO): Novel compounds and their use as positive AMPA receptor modulators. WO-09942456 (1999).
156. ASTRA AB (Phillips E, Mack R, Macor J, Semus S): Novel spiroazabicyclic heterocyclic compounds. WO-09903859 (1999).